Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
NCT01949532
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed Multiple Myeloma
End-stage Renal Disease
Interventions
DRUG:
Carfilzomib
Sponsor
Amgen